Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sorbitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL21327681 | 1.00 | LMNA (0.73) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL5050555 | 1.00 | LMNA (0.73) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Adonitol SCHEMBL27608468 | 0.93 | TDP1 (0.67) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL18429950 | 0.93 | TDP1 (0.67) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL3936883 | 0.91 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28076153 | 0.91 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL9456465 | 0.90 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL26129004 | 0.87 | LMNA (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL6244361 | 0.86 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28032309 | 0.86 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116235855-A | Suspended seed coating agent containing sodium alginate oligosaccharide and preparation and application thereof | 中国科学院大连化学物理研究所 | 2023-06-09 | — | — | CN | claimed |
| US-11147992-B2 | Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy | COLGATE-PALMOLIVE COMPANY (US) | 2021-10-19 | — | — | US | claimed |
| EP-3348260-B1 | PHARMACEUTICAL TRAMADOL COMPOSITION FOR OPHTHALMIC USE | FARMALIDER SA (ES) | 2021-06-02 | — | — | EP | claimed |
| US-20200054900-A1 | Low Water Stannous Fluoride Plus Zinc Citrate Dentifrice with Improved Stability, Rheology, and Efficacy | COLGATE-PALMOLIVE COMPANY (US) | 2020-02-20 | — | — | US | claimed |
| US-20190224114-A1 | PHARMACEUTICAL TRAMADOL COMPOSITION FOR OPHTHALMIC USE | FARMALIDER, S.A. (ES) | 2019-07-25 | — | — | US | claimed |
| WO-2018237161-A1 | PRESERVATIVE SYSTEM FOR SMOKE-ABLE SHELLS | NATIONAL TOBACCO COMPANY, L.P. (US) | 2018-12-27 | — | — | WO | claimed |
| EP-3348260-A1 | PHARMACEUTICAL TRAMADOL COMPOSITION FOR OPHTHALMIC USE | Farmalider, S.A. (ES) | 2018-07-18 | — | — | EP | claimed |
| WO-2004039390-A1 | OINTMENT COMPOSITION FOR TREATING DECUBITUS ULCERS AND METHODS FOR ITS MAKING AND ITS USE | GOULBOURNE MARY J (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040013744-A1 | Ointment composition for treating decubitus ulcers and methods for its making and its use | GOULBOURNE MARY J (US) | 2004-01-22 | — | — | US | claimed |
| US-5641498-A | FILM FORMING BLENDS COMPRISING POLYVNYL ALCOHOL AND CHLORHEXIDINE SALT MICROBIOCIDES | IBA, INC. (US) | 1997-06-24 | — | — | US | claimed |
| US-20240008967-A1 | Method of Electrochemically Boosting Tooth Whitening | COLGATE-PALMOLIVE COMPANY (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2023156293-A1 | IMPROVED PROCESS AND DEVICE FOR MAKING AQUEOUS WELLBORE TREATING FLUIDS | BASF SE (DE) | 2023-08-24 | — | — | WO | disclosed |
| EP-4203844-A1 | METHOD OF ELECTROCHEMICALLY BOOSTING TOOTH WHITENING | Colgate-Palmolive Company (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| EP-3436561-B1 | ENHANCED SOLUBILIZATION USING A COMBINATION OF EXTENDED CHAIN SURFACTANTS | INDORAMA VENTURES OXIDES LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-4687663-A | HYDROGEN PEROXIDE AND SODIUM BICARBONATE FOR CLEANING TEETH | JPMORGAN CHASE BANK, AS ADMINISTRATIVE AGENT | 1987-08-18 | — | — | US | disclosed |
| US-4465666-A | TOPICAL HERPES VIRICIDE, SULFATED POLYSACCHARIDE, HEPARIN, ZINC COMPOUND | CIBA-GEIGY CORPORATION (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0024578-B1 | METHOD OF STABILIZING AN ENZYME SOLUTION FOR USE IN TOTAL CHOLESTEROL DETERMINATION, STABILIZED SOLUTION AND TEST KIT THEREFOR | Modrovich, Ivan Endre (US) | 1983-12-07 | — | — | EP | disclosed |
| US-4348381-A | Dental remineralization composition | COLGATE-PALMOLIVE COMPANY (US) | 1982-09-07 | — | — | US | disclosed |
| US-4073783-A | PENICILLINS | PFIZER INC. (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | GPX4, GPX1, AIFM2 | LMNA 1051/4885L3MBTL1 129/4885TDP1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.